World Health Organization Raises Concern Over Acute Lack of Weight-Loss Medications
Fewer than 10% of individuals who could benefit from obesity jabs like Wegovy can access them, warns the global health agency as it issues its initial recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging broader and more equitable availability to this class of drugs.
Per estimates, over two billion are projected to be living with obesity by 2030 unless action is taken.
"The new guidelines acknowledges that obesity is a chronic disease that can be managed with thorough and continuous support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are key hurdles to broad access to the injections that can assist patients in reducing substantial body mass, explains the organization.
Weight-Loss Drug Shortage
Even in the present best projected outlook, the production of GLP-1 therapies might only reach approximately 100 million people – less than 10% of eligible patients, according to the WHO.
The guideline encourages countries and companies to expand access, by approaches such as voluntary licensing.
Exclusive production rights on semaglutide – the main component of a leading brand – is due to expire in a number of countries in 2026.
How Obesity Jabs Operate
These medications mimick a natural hormone to delay gastric emptying, curb appetite and boost feelings of fullness so people reduce food intake.
Patients commonly see weight reduction within a few weeks of starting on the once-weekly jabs.
Studies indicates people may regain a significant portion after a year of discontinuing the medication, because their normal food cravings resume.
To be overweight or obese increases your chance for experiencing diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and some cancers.
Obesity concerns individuals in all nations and was linked to over three and a half million deaths worldwide in 2024, according to the WHO.
